Analysts advised investors to subscribe to Concord Biotech IPO given its complex product portfolio, presence in niche space, strong client relationship and high entry barriers. The company is one of the leading global manufacturers of select fermentation-based APIs (F-APIs) across immunosuppressants and oncology with a market share of over 20% by volume in 2022.
Standard deviation studies pointing Nifty at 25,000 and beyond: Anand James
Anand James of Geojit Investments sees potential for Nifty to hit 25,000, though warns that a drop below 24,280 may signal weakness. He expects defence